Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P04637 (
p53
)
77,613
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Human
SIRT1
controls various physiological responses including cell fate, stress, and aging, through deacetylation of its specific substrate protein. In processing DNA damage signaling,
SIRT1
attenuates a cellular apoptotic response by deacetylation of
p53 tumor suppressor
. The present study shows that, upon exposure to radiation,
SIRT1
could enhance DNA repair capacity and deacetylation of repair protein Ku70. Ectopically over-expressed
SIRT1
resulted in the increase of repair of DNA strand breakages produced by radiation. On the other hand, repression of endogenous
SIRT1
expression by
SIRT1
siRNA led to the decrease of this repair activity, indicating that
SIRT1
can regulate DNA repair capacity of cells with DNA strand breaks. In addition, we found that
SIRT1
physically complexed with repair protein Ku70, leading to subsequent deacetylation. The dominant-negative
SIRT1
, a catalytically inactive form, did not induce deacetylation of Ku70 protein as well as increase of DNA repair capacity. These observations suggest that
SIRT1
modulates DNA repair activity, which could be regulated by the acetylation status of repair protein Ku70 following DNA damage.
...
PMID:SIRT1 promotes DNA repair activity and deacetylation of Ku70. 1733 24
Bcr-Abl-independent signaling pathways are known to be involved in imatinib resistance in some patients with chronic myelogenous leukemia (CML). In this study, to find new targets for imatinib-resistant CML displaying loss of Bcr-Abl kinase target dependence, we isolated imatinib-resistant variants, K562/R1, K562/R2, and K562/R3, which showed profound declines of Bcr-Abl levels and its tyrosine kinase activity, from K562 cells. Importantly, the imatinib resistance mechanism in these variants also included aberrant acetylation of nonhistone proteins such as
p53
, Ku70, and Hsp90 that was due to upregulation of histone deacetylases (HDACs) and down-regulation of histone acetyltransferase (HAT). In comparison with K562 cells, the imatinib-resistant variants showed up-regulation of HDAC1, -2, and -3 (class I HDACs) and class III
SIRT1
and down-regulation of CBP/p300 and PCAF with HAT activity, and thereby
p53
and cytoplasmic Ku70 were aberrantly acetylated. In addition, these were associated with down-regulation of Bax and up-regulation of Bcl-2. In contrast, the class II HDAC6 level was significantly decreased, and this was accompanied by an increase of Hsp90 acetylation in the imatinib-resistant variants, which was closely associated with loss of Bcr-Abl. These results indicate that alteration of the normal balance of HATs and HDACs leads to deregulated acetylation of Hsp90,
p53
, and Ku70 and thereby leads to imatinib resistance, suggesting the importance of the acetylation status of apoptosis-related nonhistone proteins in Bcr-Abl-independent imatinib resistance. We also revealed that imatinib-resistant K562 cells were more sensitive to suberoylanilide hydroxamic acid, an HDAC inhibitor, than K562 cells. These findings may have implications for HDAC as a molecular target in imatinib-resistant leukemia cells.
...
PMID:Bcr-Abl-independent imatinib-resistant K562 cells show aberrant protein acetylation and increased sensitivity to histone deacetylase inhibitors. 1756 22
A progressive loss of neurons with age underlies a variety of debilitating neurological disorders, including Alzheimer's disease (AD) and amyotrophic lateral sclerosis (ALS), yet few effective treatments are currently available. The SIR2 gene promotes longevity in a variety of organisms and may underlie the health benefits of caloric restriction, a diet that delays aging and neurodegeneration in mammals. Here, we report that a human homologue of SIR2,
SIRT1
, is upregulated in mouse models for AD, ALS and in primary neurons challenged with neurotoxic insults. In cell-based models for AD/tauopathies and ALS,
SIRT1
and resveratrol, a
SIRT1
-activating molecule, both promote neuronal survival. In the inducible p25 transgenic mouse, a model of AD and tauopathies, resveratrol reduced neurodegeneration in the hippocampus, prevented learning impairment, and decreased the acetylation of the known
SIRT1
substrates PGC-1alpha and
p53
. Furthermore, injection of
SIRT1
lentivirus in the hippocampus of p25 transgenic mice conferred significant protection against neurodegeneration. Thus,
SIRT1
constitutes a unique molecular link between aging and human neurodegenerative disorders and provides a promising avenue for therapeutic intervention.
...
PMID:SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer's disease and amyotrophic lateral sclerosis. 1758 37
It has been reported that
p53
acetylation, which promotes cellular senescence, can be regulated by the NAD(+)-dependent deacetylase
SIRT1
, the human homolog of yeast Sir2, a protein that modulates lifespan. To clarify the role of
SIRT1
in cellular senescence induced by oxidative stress, we treated normal human diploid fibroblast TIG-3 cells with H(2)O(2) and examined DNA cleavage, depletion of intracellular NAD(+), expression of p21,
SIRT1
, and acetylated
p53
, cell cycle arrest, and senescence-associated beta-galactosidase (SA-beta-gal) activity. DNA cleavage was observed immediately in TIG-3 cells treated with H(2)O(2), though no cell death was observed. NAD(+) levels in TIG-3 cells treated with H(2)O(2) were also decreased significantly. Pre-incubation with the poly (ADP-ribose) polymerase (PARP) inhibitor resulted in preservation of intracellular NAD(+) levels. The amount of acetylated
p53
was increased in TIG-3 cells at 4h after H(2)O(2) treatment, while there was little to no decrease in SIRT1 protein expression. The expression level of p21 was increased at 12h and continued to increase for up to 24h. Additionally, exposure of TIG-3 cells to H(2)O(2) induced cell cycle arrest at 24h and increased SA-beta-gal activity at 48h. This pathway likely plays an important role in the acceleration of cellular senescence by oxidative stress.
...
PMID:H2O2 accelerates cellular senescence by accumulation of acetylated p53 via decrease in the function of SIRT1 by NAD+ depletion. 1759 14
The activity of Rb (retinoblastoma protein) is regulated by phosphorylation and acetylation events. Active Rb is hypophosphorylated and acetylated on multiple residues. Inactivation of Rb involves concerted hyper-phosphorylation by cyclin-CDK (cyclin-dependent kinase) complexes combined with deacetylation of appropriate lysine residues within Rb. In the present study, using in vivo co-immunoprecipitation experiments, we identified mammalian
SIRT1
(sirtuin 1) as a binding partner for Rb and its family members p107 and p130. Formation of Rb-
SIRT1
complexes required the pocket domain of Rb. p300 catalysed the acetylation of Rb, and
SIRT1
was a potent deacetylase for Rb. The ability of
SIRT1
to catalyse the deacetylation of Rb was dependent on NAD and was inhibited by the
SIRT1
inhibitor nicotinamide. Deacetylated lysine residues within Rb formed a domain similar to the
SIRT1
-targeted domain of the
p53
tumour suppressor protein. Cultures of arrested cells, via contact inhibition or DNA damage, exhibited decreased Rb phosphorylation and increased Rb acetylation. Overexpression of
SIRT1
in either confluent or etoposide-treated cells resulted in a significant reduction in Rb acetylation, which was restored with nicotinamide. Gene knockdown of
SIRT1
by siRNA (short interfering RNA) produced an accumulation of acetylated Rb. This increase was augmented further when siRNA against
SIRT1
was used in conjunction with nicotinamide. In conclusion, our results demonstrate that
SIRT1
is an in vitro and in vivo deacetylase for the Rb tumour suppressor protein.
...
PMID:Deacetylation of the retinoblastoma tumour suppressor protein by SIRT1. 1762 57
The NAD(+)-dependent protein deacetylase
SIRT1
is linked to cellular survival pathways by virtue of keeping the tumor suppressor gene
p53
and members of the forkhead transcription factor family deacetylated. To validate
SIRT1
as a therapeutic anti-cancer target, we performed immunohistochemistry experiments to study the in vivo expression of
SIRT1
in cancer specimens. We show that human
SIRT1
is highly expressed in cancer cell lines as well as in tissue samples from colon carcinoma patients. Interestingly, there is a strong cytosolic component in the
SIRT1
expression pattern. We further characterized
SIRT1
in
p53
-wild-type and -mutant cell lines and show that
SIRT1
mRNA-knockdown leads to a
p53
-independent decrease of cell proliferation and induction of apoptosis. In addition,
SIRT1
expression has been found to be inducible upon DNA damage. A previously discovered small molecule
SIRT1
inhibitor with nanomolar in vitro activity has been tested in cancer relevant assays. The
SIRT1
inhibitory compound showed no potent anti-proliferative activity despite hitting its molecular target within tumor cells. From these studies we conclude that it may not be sufficient to block the catalytic function of
SIRT1
, and that its survival effects may be mainly brought about by means other then the deacetylase function. The increased cytosolic expression of
SIRT1
in cancer cells could be an indicator of such novel functions.
...
PMID:Function of the SIRT1 protein deacetylase in cancer. 1780 2
Gankyrin is an oncoprotein commonly overexpressed in hepatocellular carcinomas. It interacts with multiple proteins and accelerates degradation of tumor suppressors Rb and
p53
. Since gankyrin consists of 7 ankyrin repeats and is structurally similar to IkappaBs, we investigated its interaction with NF-kappaB. We found that gankyrin directly binds to RelA. In HeLa and 293 cells, overexpression of gankyrin suppressed the basal as well as TNFalpha-induced transcriptional activity of NF-kappaB, whereas down-regulation of gankyrin increased it. Gankyrin did not affect the NF-kappaB DNA-binding activity or nuclear translocation of RelA induced by TNFalpha in these cells. Leptomycin B that inhibits nuclear export of RelA suppressed the NF-kappaB activity, which was further suppressed by gankyrin. The inhibitory effect of gankyrin was abrogated by nicotinamide as well as down-regulation of
SIRT1
, a class III histone deacetylase. Thus, gankyrin binds to NF-kappaB and suppresses its activity at the transcription level by modulating acetylation via
SIRT1
.
...
PMID:The oncoprotein gankyrin interacts with RelA and suppresses NF-kappaB activity. 1790 23
Human
SIRT1
is an NAD+-dependent deacetylase protein that plays a role in cell death/survival, senescence, and endocrine signaling. While its substrates, including
p53
, have been well characterized, no direct regulators are known. We describe here a nuclear protein, active regulator of
SIRT1
(AROS), which directly regulates
SIRT1
function. AROS enhanced
SIRT1
-mediated deacetylation of
p53
both in vitro and in vivo, and it inhibited
p53
-mediated transcriptional activity. AROS activity was abrogated by the
SIRT1
inhibitors splitomicin and nicotinamide and by
SIRT1
small interfering RNA (siRNA). In addition, AROS was unable to cooperate in
p53
inactivation in an AROS-binding-defective
SIRT1
mutant. Finally, knockdown of endogenous AROS using an antisense expression vector enhanced p21WAF1 expression and increased both the G0/G1 population and apoptosis in response to DNA damage, while AROS overexpression improved cell survival. To our knowledge, AROS is the first direct
SIRT1
regulator to be identified that modulates
p53
-mediated growth regulation.
...
PMID:Active regulator of SIRT1 cooperates with SIRT1 and facilitates suppression of p53 activity. 1799 99
SIRT1
is a protein deacetylase that regulates cellular responses to a variety of stresses. In a recent issue of Molecular Cell, Kim et al. (2007) report the identification of a cellular protein, AROS, that activates the
SIRT1
-mediated deacetylation of
p53
.
...
PMID:AROuSing SIRT1: identification of a novel endogenous SIRT1 activator. 1796 66
Werner syndrome is an autosomal recessive disorder associated with premature aging and cancer predisposition caused by mutations of the WRN gene. WRN is a member of the RecQ DNA helicase family with functions in maintaining genome stability. Sir2, an NAD-dependent histone deacetylase, has been proven to extend life span in yeast and Caenorhabditis elegans. Mammalian Sir2 (
SIRT1
) has also been found to regulate premature cellular senescence induced by the tumor suppressors PML and
p53
.
SIRT1
plays an important role in cell survival promoted by calorie restriction. Here we show that
SIRT1
interacts with WRN both in vitro and in vivo; this interaction is enhanced after DNA damage. WRN can be acetylated by acetyltransferase CBP/p300, and
SIRT1
can deacetylate WRN both in vitro and in vivo. WRN acetylation decreases its helicase and exonuclease activities, and
SIRT1
can reverse this effect. WRN acetylation alters its nuclear distribution. Down-regulation of
SIRT1
reduces WRN translocation from nucleoplasm to nucleoli after DNA damage. These results suggest that
SIRT1
regulates WRN-mediated cellular responses to DNA damage through deacetylation of WRN.
...
PMID:Regulation of WRN protein cellular localization and enzymatic activities by SIRT1-mediated deacetylation. 1820 16
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>